MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches

Nicola Amodio*, Lavinia Raimondi**, Giada Juli**, Maria Angelica Stamat**, Daniele Caracciolo*, Piersandro Tagliaferri and Pierfrancesco Tassone*

Abstract
The deeper understanding of non-coding RNAs has recently changed the dogma of molecular biology assuming protein-coding genes as unique functional biological effectors, while non-coding genes as junk material of doubtful significance. In the last decade, an exciting boom of experimental research has brought to light the pivotal biological functions of long non-coding RNAs (lncRNAs), representing more than the half of the whole non-coding transcriptome, along with their dysregulation in many diseases, including cancer.

In this review, we summarize the emerging insights on lncRNA expression and functional role in cancer, focusing on the evolutionary conserved and abundantly expressed metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) that currently represents the best characterized lncRNA. Altogether, literature data indicate aberrant expression and dysregulated activity of MALAT1 in human malignancies and envision MALAT1 targeting as a novel treatment strategy against cancer.

Keywords: MALAT1, Long non-coding RNA, lncRNA, Non-coding RNA, Epigenetics, Experimental therapeutics

Background
Long non-coding RNAs (lncRNAs): classification and mechanisms of action
Deep analysis of the human transcriptome has estimated that while three quarters of the human genome is actively transcribed, only the 3% is represented by protein-coding genes. While such a huge non-coding genome was considered transcriptional noise and neglected until the last decade, its biological relevance is nowadays well-acknowledged and represents a matter of intense investigation.

Different types of classification for non-coding RNAs (ncRNAs) have been so far adopted. Based on their length, ncRNAs can be classified into short (< 200 nucleotides) or lncRNAs (> 200 nucleotides) [1]. lncRNAs are the most abundant class of ncRNAs involved in important biological processes, such as epigenetic control of gene expression, promoter-specific transcriptional regulation [2], X chromosome inactivation [3, 4], genomic imprinting [5, 6], and cell differentiation and development [7]; consistent with a role in these processes, it is not surprising that lncRNAs are found dysregulated in different human diseases, including cancer [8]. Overall, these RNA molecules do not show protein-coding potential, localize predominantly to the nucleus, and are generally less expressed than protein-coding genes, while displaying more tissue-specific expression patterns; moreover, lncRNAs generally undergo splicing and can be polyadenylated [1, 9].

Based on molecular function, lncRNAs can be distinguished in the following:

(a) lncRNAs signal that regulate the transcription by interacting with transcription factors (TFs), and activate or repress their activity;
(b) lncRNAs decoy that displace TFs and other proteins from chromatin of which they are negative regulators;
(c) lncRNAs scaffold that bind multiple proteins and facilitate the formation of ribonucleoprotein complexes;
(d) lncRNAs guide, acting as guidance molecules for chromatin-modifying protein complexes to target genes [10].
While cis-acting RNAs are limited to the site of synthesis and operate on one or more genes on the same chromosome, trans-acting RNAs move from the site of synthesis and exert their function at larger distances or even on other chromosomes [11]. Moreover, IncRNAs can modulate the mRNA life cycle in the cytoplasm through different mechanisms, including the following:

(a) mRNA stability regulation by Staufen 1 (STAU1)-mediated decay, in which base-pairing of ALU elements located in the IncRNA and the target mRNA creates a double-stranded STAU1-binding site that can direct exosome mediated RNA degradation [12];
(b) RNA splicing regulation by direct association between IncRNAs and splicing factors;
(c) RNA editing regulation with activation of ADAR enzymes induced by the interaction of antisense IncRNA and sense mRNA [11];
(d) miRNA sponges that contain multiple binding sites for one or more miRNAs and regulate target mRNA expression by sequestering miRNAs away from their mRNA targets [13, 14].

LncRNAs can be also classified according to their genomic location with respect to the nearest protein-coding genes. In this regard:

(a) Long intergenic non-coding RNAs (lincRNAs) are ncRNAs which do not lie close to protein-coding genes;
(b) Sense IncRNAs are on the same strand of protein-coding genes and are transcribed in the same direction;
(c) Antisense IncRNAs lie on the opposite strand of protein-coding genes with which they overlap (if the overlap is partial, IncRNAs are defined natural antisense transcripts);
(d) Intronic antisense lncRNAs and bidirectional IncRNAs that locate on the other strand with respect to protein-coding genes and are transcribed in the opposite direction [15, 16].

Several lncRNA databases providing relevant information on lncRNA structure and functional role are currently available. Noteworthy, LNCipedia annotates human IncRNA sequences and structures [17], while IncRNAdb contains information about IncRNA biological functions and expression in different biological systems [18]. The GENCODE consortium includes human genome annotation for the ENCODE project [19], while the NONCODE database (v3.0 and 4.0) has extended available information on lncRNA cellular localization, function and expression to the cancer setting [20, 21]. For in-depth information on lncRNA databases, we recommend to the readers more specialized reviews [22].

Cancer-related mechanisms of lncRNA dysregulation

LncRNAs have emerged as novel master regulators of initiation, progression, and response to therapy in a wide variety of solid tumors and hematological malignancies. Compelling evidence supports aberrant patterns of expression of lncRNAs in cancer [16], which may occur through various mechanisms, summarized in Table 1.

### Genomic alterations

Deletions or amplification of gene loci may be responsible of abnormal expression of lncRNAs in cancer. Deleted in leukemia 1 (DLEU1) and 2 (DLEU2) are two IncRNAs whose genes map in a critical region at chromosome 13q14.3 deleted in more than 50% of chronic lymphocytic leukemia (CLL) patients [23], and hosting miR-15a and 16–1, a miRNA tumor suppressive cluster [24]. Mice deleted for the entire minimal deleted region within 13q14, comprising DLEU2 gene, developed clonal B cell proliferations resembling human CLL [25, 26]. LncRNA expression profiling of the major forms of plasma cell dyscrasias highlighted significant downregulation of DLEU2 in patients carrying del13 [27].

| Mechanism | IncRNA | Effect on lncRNA expression |
|-----------|--------|----------------------------|
| Chromosomal deletion | DLEU1/2 | Downregulation | [23] |
| Chromosomal amplification | PVT1 | Upregulation | [28] |
| Polymorphisms in enhancer regions | HOTAIR | Upregulation | [29] |
| CpG methylation | KIAA0495 | Downregulation | [32] |
| CpG methylation | MEG3 | Downregulation | [34] |
| p53 | lincRNA-p21 | Upregulation | [40] |
| p53 | PINT | Upregulation | [41] |
| p53 | H19 | Downregulation | [42] |
| MYC | MYCLo1/2 | Upregulation | [46] |
| MYC | PCAT1 | Upregulation | [50] |
| MYC | H19 | Upregulation | [55] |
| MYC | HOTAIR | Upregulation | [29] |
| Notch1 | LUNAR | Upregulation | [58] |
| Notch1 | NALT | Upregulation | [59] |
| ER | DSCLCAM-AS1 | Upregulation | [63] |
| ER | NEAT1 | Upregulation | [64] |

Amodio et al. Journal of Hematology & Oncology (2018) 11:63
apoptosis and reduced survival of cancer cell lines [28]. The presence of tumor-associated single nucleotides polymorphisms (SNPs) within enhancer regions of certain lncRNAs, including HOXAIR, may also drive their dysregulated expression and was found to correlate with high risk of tumor development [29].

Epigenetic alterations

Epigenetic modifications account for aberrant expression of short ncRNAs [30], but are also implicated in lncRNA dysregulation. Zhang and colleagues integrated multiomics data to assess alterations of lncRNA methylation in breast invasive carcinoma, highlighting abnormally methylated lncRNAs involved in several hallmarks of cancers [31]. In multiple myeloma (MM) cells, the methylation of promoter-associated CpG islands triggered downregulation of KIAA0495, a lncRNA transcribed from chromosome 1p36 [32]; CpG island hypermethylation also downregulated the KIAA0495/p53-dependent apoptotic modulator PDAM, which in turn established a drug resistant phenotype in glioma cells [33].

Aberrant promoter methylation of the imprinted lncRNA gene MEG3 was described in acute myeloid leukemia and myelodysplastic syndromes patients, where MEG3 methylation status negatively correlated with overall survival [34]; MEG3 promoter hypermethylation has been also reported in MM [35] and in esophageal squamous cell carcinoma (ESCC) [36].

P53-dependent regulation

Several factors involved in cellular homeostasis may regulate lncRNA expression. For instance, similarly to miRNAs [37], some lncRNAs have been found associated with the p53 tumor suppressor pathway [38, 39]. P53 bound to and transcriptionally activated the promoter of lncRNA-p21 that resides 15Kb upstream of the gene encoding the cell cycle regulator CDKN1A; in turn, lncRNA-p21 mediated p53-dependent induction of cell death by repressing gene expression partly through interaction with the heterogeneous nuclear ribonucleoprotein k (hnRNP-k) [40]. Marin-Bejar et al. showed that p53 activates PINT, a lncRNA downregulated in colon tumors, whose enforced expression decreased in vitro proliferation of cancer cell lines [41]; moreover, p53 may also repress the promoter of the H19 lncRNA [42], a maternally imprinted gene overexpressed in fetal tissues and silenced after birth, initially described as tumor suppressor [43], but also endowed with oncogenic properties in certain tissues. Accordingly, high levels of H19 prompted tumorigenesis by negatively regulating p53 activity in gastric cancer [44], since miR-675, the mature product of H19, can directly target and down-regulate p53 [45].

MYC-dependent regulation

c-MYC oncogene can also account for lncRNA regulation in tumor cells. MYCLos are MYC-regulated lncRNAs positively mediating MYC-mediated tumorigenesis, whose promoters are highly enriched for Myc-binding sites. In the nucleus, MYCLo-1 and MYCLo-2 physically interact with HuR and hnRNPK RNA-binding proteins respectively, finally repressing CDKN1A and CDKN2B transcription [46–48]. RNA-Seq analysis of the prostate cancer transcriptome identified 121 unannotated ncRNA transcripts, of which PCAT-1 (prostate cancer-associated transcript 1) is a sense lncRNA localized upstream of the MYC gene at the 8q24 genomic region [49]. Prensner et al. showed that prostate cell proliferation promoted by PCAT-1 was c-MYC dependent; in turn, PCAT-1 increased MYC 3’UTR activity and exerted a protective effect on tumor cells by abolishing miR-34a-dependent targeting of c-MYC [50–52]. c-MYC also binds to the E-boxes located in the H19 gene promoter, thus facilitating histones acetylation and transcription of the H19 gene [53–56].

The human PVT1 lncRNA is located on chromosome 8 telomeric to the c-Myc gene and is frequently involved in the translocations occurring in variant Burkitt’s lymphomas and murine plasmacytoma; PVT1 presents two MYC-binding sites in its promoter, which are bound and transactivated by c-MYC [57].

c-MYC-dependent transcriptional activation through E-box located upstream of the transcription start site also accounted for elevated expression of the oncogenic lncRNA HOTAIR in human cancer [29].

Notch-1-dependent regulation

Notch1/RBPJk-binding sites have been detected in several lncRNA promoters. Trimarchi et al. showed that Notch mediates the transcriptional activation of several lncRNAs in T-acute lymphoblastic leukemias (T-ALL). The leukemia-induced non-coding activator RNA LUNAR1 was discovered as Notch-regulated oncogenic lncRNA in T-ALL cells, which promoted cancer cell proliferation by activation of IGF-1 signaling [58]. The lncRNA RP11-611D20.2, also named NALT (Notch1 associated lncRNA in T-ALL), was found located near Notch1 gene, and its overexpression sustained in vitro and in vivo T-ALL growth [59].

ER-mediated regulation

Estrogen receptor (ER) signaling was shown to be involved in tumorigenesis through the regulation of a subset of lncRNAs. Deep sequencing analysis following estrogen stimulation [60–62] highlighted 133 lncRNAs associated with luminal histotype of breast cancer, of which DSCAM-AS1 was found predominantly expressed in ERα+ cases, but not in ERα− and in pre-neoplastic
lesions. DSCAM-AS1 knockdown recapitulated the effects caused by ERα silencing, as the arrest of cancer cell growth and induction of EMT [63]. In the study by Chakravarty et al., the nuclear-enriched abundant transcript 1 (NEAT1) was among the top ERα-regulated IncRNAs in prostate cancer as compared with benign prostate tissues; in prostate cancer cell lines, ERα overexpression upregulated NEAT1 [64], which in turn activated the transcription of genes involved in prostate cancer progression [64].

MALAT1 is the first discovered and most widely investigated IncRNA, in terms of both functional activity and therapeutic potential for cancer treatment [65].

Different molecular mechanisms have been implicated in MALAT1 dysregulation in human cancer, and will be in-depth analyzed in the next paragraphs.

**MALAT1 expression and regulation**

The transcript of MALAT1 gene, also known as NEAT2 for nuclear-enriched abundant transcript 2, consists of >8000 nucleotides as described by Ji et al. [65]. Although early reports provided evidence of its association with metastasis in early-stage non-small cell lung cancer (NSCLC) patients, subsequent studies reported that MALAT1 is extremely abundant and widely conserved among 33 mammalian species [65, 66]. Later, MALAT1 was reported to be a highly abundant nuclear transcript localized to the nuclear speckles, a nuclear domain for storage and/or the sites of pre-mRNA splicing; computational and biochemical studies then confirmed interaction between MALAT1 and serine- and arginine-rich (SR) proteins involved in splicing regulation, or with spliceosomal proteins [67].

MALAT1 is transcribed by RNA polymerase II from the human chromosome 11q13. Its biogenesis relies on the tRNA processing machinery, by a regulatory mechanism that allows a single locus to produce two non-coding RNAs that localize to different subcellular compartments and have distinct functions. In detail, the tRNA-like structure at 3′ end of the primary transcript is cleaved by tRNA endonucleases RNase P and RNase Z, generating both a long transcript localizing to nuclear bodies with a short poly(A) tail-like moiety, and a smaller 61-nucleotides MALAT1-associated small cytoplasmic RNA (mascRNA) that is exported to the cytoplasm. The mascRNA folds similar to a tRNA cloverleaf secondary structure, allowing it to be recognized by several members of the canonical tRNA processing machinery [68, 69].

MALAT1 half-life (9–12 h) is longer than other IncRNAs, probably for the presence of a triple helix structure at its 3′ end that confers stability by engaging a downstream A-rich tract [70].

Noteworthy, the nuclear methyltransferase-like protein 16 (METTL16) was shown to interact with the MALAT1 triple-helix in vitro and in vivo [71] and to catalyze the N(6)-methyladenosine (m6A) modification, a reversible post-transcriptional modification of MALAT1 hairpin that facilitates the accessibility of a U5-tract for the binding to hnRNP C, a nuclear protein necessary for pre-mRNA processing [72].

A relevant interactor of MALAT1 is TAR DNA-binding protein TDP43 located in the mouse brain. TDP43 is a predominantly nuclear protein that regulates transcription, alternative splicing and RNA stability [73]. In human brains from subjects with fronto-temporal lobar degeneration having TDP-43 inclusions (FTLD-TDP), binding of MALAT1 to TDP43 increased, thus suggesting a link between MALAT1 and neurodegenerative diseases [74].

MALAT1 undergoes a tight transcriptional control in tumor cells. Several transcription factors can regulate MALAT1 transcription, either in a positive manner, as SP1, SP3 [75], β-catenin [76], HIF1α [77] and HIF2α [78], c-MYC [79], Yes-associated protein 1 (YAP1) [80], NRF1 [81], or in a negative fashion, like p53 [82] and SOX17 [83]. Moreover, hormones, such as oxytocin [84], or growth factors, such as TGF-β [85], can transcriptionally induce MALAT1 leading to tumor growth.

The Drosha-DGCR8 complex, a component of miRNA biogenesis machinery, was found to interact with the 5′ end of MALAT1 and to regulate its stability [86]. The involvement of miRNAs in MALAT1 expression regulation was further corroborated by the study of Leucci et al., who showed that depletion of Ago2 stabilized MALAT1, thus suggesting that miRNAs play a role in MALAT1 modulation; accordingly, miR-9 was shown to target MALAT1 for degradation in the nucleus by directly binding to two miRNA-binding sites within MALAT1 sequence [87]. Furthermore, Ago2-dependent post-transcriptional regulation of MALAT1 by miR-101 and miR-217 significantly impaired proliferation, migration, and invasion of Esophageal Squamous Cell Carcinoma Cells (ESCC) cells, highlighting the MALAT1-dependent tumor suppressor role of these miRNAs [88].

A massive parallel sequence analysis of small RNAs intriguingly identified a number of MALAT1-derived miRNA-like molecules, whose functions is yet to be determined [86].

Epigenetic histone modifications may also regulate MALAT1. For instance, Jumonji C-domain-containing protein JMJD1A, a H3K9 histone demethylase, was found to bind to MALAT1 promoter, and to demethylate histone H3 at lysine 9 (H3K9), thus leading to MALAT1 upregulation [89, 90]. KMD3A, another H3K9 demethylating enzyme, was found to induce MALAT1 expression in MM cells that contributed to the establishment of hypoxic...
niches supporting tumor growth [91]. Conversely, lysine-specific demethylase 5B KDM5B suppressed MALAT1 expression via miR-448 upregulation that directly targeted MALAT1 [92].

A graphic overview of the molecular mechanisms underlying MALAT1 expression is provided in Fig. 1.

MALAT1 molecular functions
To date, three major functions have been attributed to MALAT1 (see Fig. 2 for a graphic overview). The contribution of each function to the tumorigenic activity of MALAT1 within specific tumor types will be also discussed in the paragraph “MALAT1 role in cancer”.

Alternative splicing
Regulation of alternative splicing is the first identified function for MALAT1. As mentioned before, MALAT1 was found localized in the nucleus, and specifically enriched at nuclear speckle periphery [93]; here, MALAT1 interacted with SR proteins, such as SRSF1, SRSF2, and SRSF3, and its depletion impaired the phosphorylation and the expression pattern of SR proteins, ultimately affecting pre-mRNAs alternative splicing [94] (Fig. 2a); interestingly, silencing of splicing factors induced MALAT1 relocalization from speckles to nucleoplasm [94, 95]. The pro-tumorigenic activity of SRSF1 has been recently established [96], and a whole genome analysis has identified multiple mutations in SRSF1-binding sites of MALAT1, pointing to a role for SRSF1/MALAT1 interaction in cancer pathogenesis [97].

Regulation of alternative splicing by MALAT1 is however under debate, since nuclear speckle components and alternative splicing are not impaired in mouse embryonic fibroblasts generated from MALAT1 knockout mice, thus indicating that MALAT1 is not essential for splicing regulation under physiological conditions [98].

Transcriptional regulation
Preliminary evidence of MALAT1 involvement in transcriptional regulation was supported by colocalization of serine-2 phosphorylated RNA polymerase II in nuclear speckle compartment. Later, MALAT1 was reported to interact with unmethylated Pc2, a component of the polycomb-repressive complex 1, together with the lncRNA TUG1.

The physical relocation of growth control genes from polycomb bodies is modulated by the methylation/demethylation of Polycomb 2 (Pc2), a component of the polycomb repressive complex 1. MALAT1 functions as a molecular scaffold that allows gene expression during serum stimulation by promoting the interaction among non-methylated Pc2, E2F TF, activation-associated histone markers, and the transcriptional coactivator complex [99]. Consistently, MALAT1 actively interacts with transcribed gene loci and controls their expression, as demonstrated by MALAT1 interaction with the 3’ end of the gene body and overlapping with H3K36me2 peaks, a marker of active transcriptional elongation [100].

Several reports have described a physical and functional interaction between MALAT1 and the members of the PRC2 complex, EZH2, Suz12, and EED. Consistently, by facilitating binding of EZH2 to its target loci, MALAT1 drives H3K27 trimethylation and repression of tumor suppressor genes or microRNAs, leading to epithelial to mesenchymal transition, migration/invasion, cell proliferation, and escape from apoptosis in several tumor types [101, 102].
A further mechanism by which MALAT1 regulates transcription is provided by interactions with transcription factors. For instance, in MM mesenchymal stem cells, MALAT1 was found to activate the transcription of LTBP3 gene, located on the same MALAT1 locus on chromosome 11q13.1, by inducing the recruitment of Sp1 on LTBP3 promoter (Fig. 2c).

**ceRNA function**

The ceRNA function provides a further mechanism by which MALAT1 can post-transcriptionally control gene expression through inhibition of miRNAs [14]. By this mechanism, MALAT1 was proven to sequester miRNAs through miRNA responsive elements (MREs) located in its sequence, thus relieving the inhibitory effects of tumor suppressor miRNAs on oncogenic targets, and leading to phenotypic changes such as cell proliferation and invasion (Fig. 2d). Coherently with this function, MALAT1 promoted STAT3 expression by binding and sequestering its major negative regulator miR-125b in oral squamous cell carcinoma cells [103], and similarly triggered malignant melanoma growth and metastasis by sponging miR-22, and consequently upregulating the miR-22 targets MMP14 and Snail [104].

**Strategies for MALAT1 therapeutic targeting in cancer**

A huge body of preclinical data indicates that MALAT1 is abundantly expressed in human neoplasias, and promotes proliferation and/or dissemination of tumor cells of various solid and hematological malignancies; consistently, meta-analyses have reported that elevated MALAT1 correlates with larger tumor size, advanced tumor stage and overall poor prognosis, and might therefore serve as biomarker to predict either clinicopathological features or prognostic outcome of cancer patients [105, 106].

On this basis, strategies for selective inhibition of MALAT1 have been developed to halt its oncogenic activity in a therapeutic perspective. MALAT1 targeting in preclinical cancer models has been mainly achieved by the use of synthetic oligonucleotides. Although MALAT1 is located in the nucleus, and therefore is less accessible than mRNAs to siRNAs, several studies have reported its successful knockdown by RNA interference approaches [107]. Overall, inhibition of MALAT1 by siRNAs is achieved as the double-stranded RNA elicits a RISC-mediated degradation of the target lncRNA.

In addition, antisense oligonucleotides (ASOs) represent a valuable approach to antagonize MALAT1. ASOs are small oligonucleotides with RNA/DNA-based structures that selectively bind to RNA via Watson-Crick hybridization, capable to cross the cell membrane, and to bind the target RNA in the nucleus as well as in the cytoplasm [108]. Advantages of ASOs over siRNAs include their independence on the RISC machinery, higher specificity and fewer off-target effects. Most of the ASOs are...
double-stranded oligonucleotides using the RISC complex to mediate the degradation of RNA, or single-stranded ASOs that inhibit RNA function through different mechanisms, such as alteration of RNA splicing, activation of RNase H which degrades the target RNA, inhibition of 5′ cap formation and steric blockade of protein translation. Chemical modifications have been introduced to overcome some of the ASO constraints, like off-target/toxicity effects, high vulnerability to degradation by exo- and endonucleases, low affinity for the target, and poor delivery to the target tissues or low cellular uptake. These ASO modifications are defined as first generation and include a change in the phosphodiester with a phosphorothioate bond, the latter protecting the oligonucleotide from degradation and increasing the binding to receptor sites and plasma proteins [109]; conversely, second-generation modifications refer to changes in the sugar moiety of the nucleobase increasing binding affinity to the target [110]. The most relevant second-generation modification is the LNA (locked nucleic acid) [111]: this modification increases affinity, specificity and half-life determining effective delivery to target tissue with lower toxicity [108]. Finally, the third generation ASOs include peptide nucleic acid (PNA) and phosphorodiamidate morpholino oligomer (PMO) reporting modifications to the furanose ring of the nucleotide [110]. Depending on either the chemical modifications integrated into ASO or the type of inhibitory mechanism used, ASOs can be further divided in two main categories: mixmeRs and gapmeRs. In a mixmeR, LNA (locked nucleic acid) residues are dispersed throughout the ASO sequence, while gapmeRs contain a DNA or PS segment in the middle that promotes RNase H degradation of RNA target, flanked by LNAs [108]. Our group and others have demonstrated that LNA-inhibitors are efficient tools for targeting oncogenic microRNAs in preclinical models of human cancers [30, 112–122].

**MALAT1 role in cancer**

MALAT1 expression and functional role in the onset and/or progression of different cancer types, along with the therapeutic potential of MALAT1 targeting strategies, will be below discussed. A summary of clinical features of tumors with elevated MALAT1 expression, along with MALAT1 molecular targets and phenotypic effects produced by its targeting in tumor preclinical models, is reported in Table 2.

**Solid tumors**

**Lung cancer**

MALAT1 is an adverse prognostic marker both in stage I lung adenocarcinoma and squamous cell carcinoma patients, and its expression also associated with metastasis [65, 123]. Tano et al. established a link between MALAT1 and transcriptional and/or post-transcriptional modulation of genes regulating cell motility, including AIM1, LAYN, HMMR, SLC26A2, CT4, ROD1, CTHRC1, and FHL1. Schmidt then demonstrated that siRNA-mediated knockdown of MALAT1 significantly impaired migration and invasion in vitro [124], as well as in vivo tumor growth in mice. The key role of MALAT1 in metastasis was indeed disclosed by Gutschner et al., who showed that MALAT1 knock-out clones achieved by zinc finger nuclease-mediated site-specific integration of RNA destabilizing elements into the genome of lung cancer cells, failed to induce distant metastasis [125]. Mechanistically, it was demonstrated that MALAT1 modulated migration and invasion of non-small cell lung cancer (NSCLC) cells by targeting the epithelial-derived neutrophil-activating peptide belonging to the CXC chemokine family (CXCL5). The same authors showed that MALAT1 is regulated by epigenetic mechanisms, since methylation of CpG islands at MALAT1 promoter decreased in cancer as compared to normal tissues [126]. Noteworthy, Jen et al. provided evidence of transcriptional control of MALAT1 expression in lung cancer by the stemness transcription factor OCT4, which bound to MALAT1 enhancer regions and triggered its expression, thus enhancing proliferation, migration and invasion of tumor cells in vitro. Of potential clinical significance, high levels of OCT4/MALAT1 correlated with poor outcome of patients [127].

Experimental strategies targeting MALAT1 with second generation of naked ASOs demonstrated drastic reduction of lung cancer metastasis in a pulmonary metastatic model in vivo, making MALAT1 a suitable target for anti-metastatic therapy [125]. Recently, it has been also shown that MALAT1 is highly expressed in exosomes released by NSCLC cells and the levels of exosomal MALAT1 positively associated with tumor stage and lymphatic metastasis of NSCLC patients [128].

**Breast cancer**

MALAT1 overexpression in breast cancer (BC) has been reported by different research groups [129, 130]. In triple-negative breast cancer (TNBC) cells, the lysine-specific demethylase 5B (KDM5B) promoted MALAT1 expression, which in turn enhanced the invasion and clonogenic potential in in vitro and in vivo models [92]. Tumor epithelial cells overexpressing MALAT1 showed marked diffuse nuclear signals with numerous nuclear speckles [129]. Genetic loss or systemic delivery of ASOs targeting MALAT1 in the mouse mammary tumor virus-PyMT (MMTV) carcinoma model resulted in slower tumor growth, significant differentiation into cystic tumors and...
### Table 2: MALAT1-associated clinical and biological features of human cancer

| Tumor type | Associated clinical features of high MALAT1 tumors | MALAT1 molecular target(s) | Phenotypic effects induced by MALAT1 inhibition in preclinical models | References(s) |
|------------|----------------------------------------------------|--------------------------|---------------------------------------------------------------------|---------------|
| Non-small cell lung cancer | ↓ survival of stage I NSCLC patients; ↓ overall survival; ↑ metastasis; ↓ in peripheral blood of NSCLC; ↑ in advanced tumor stages and in lymph-node metastasis | AIM1, LAYN, HMAR, SLC26A2, CC14, ROD1, CTHRC1, FHL1, CXCL5 | ↓ migration and invasion in vitro; ↓ tumor growth in vivo; reduction or suppression of metastasis | [123–128] |
| Breast cancer | MALAT1-positive association with estrogen and progesterone receptors’ expression; ↓ recurrence-free survival in ER-negative patients | CD133, HuR; VEGF-A | ↓ tumor growth and differentiation into cystic tumors; metastasis reduction; ↓ branching morphogenesis; ↑ cell adhesion; ↓ migration | [129–132] [194] |
| Hepatocellular carcinoma | ↑ risk of HCC recurrence after liver transplantation; ↑ in sera of arsenite-exposed people and of HCC patients; ↑ in III-IV TNM stages; ↓ overall survival of HCC patients | TRF2; p53; HIF2α | ↓ in vitro and in vivo tumor growth | [78, 141–145] |
| Ovarian cancer | Correlation with FIGO stages; ↑ in peripheral blood correlating with distant metastasis | Matrix metalloproteinases; miR-506 | ↓ cell proliferation, migration and invasion; ↓ G0/G1 cell cycle arrest; ↑ of apoptosis | [161–164] [195, 196] |
| Cervical cancer | ↑ lymph-node metastasis; ↓ overall survival | Vimentin, β-catenin and E-cadherin | ↓ cell viability and proliferation in vitro and in vivo; ↓ migration and invasion | [135–139] |
| Esophageal cancer | ↓ survival of patients undergoing radical resection of middle thoracic ESCC; positive correlation with pT stage and negative correlation with disease-free and overall survival; ↑ lymph nodes metastasis; ↓ disease-free survival | β-catenin; Lin28; EMT/stemness-related genes (OCT4, E-cadherin) | ↓ in vitro cell growth; ↓ colony formation ability, migratory and invasive capabilities; ↓ G2/M phase cell cycle arrest and ↑ of apoptosis; ↓ tumor sphere formation; ↓ tumor formation in vivo | [147, 148] |
| Renal cell carcinoma | ↓ overall survival | Twist, E-cadherin, EZH2, miR-200, ZEB2 | ↓ cell proliferation and invasion | [169–172] |
| Prostate cancer | ↑ of PSA-positive biopsies; ↑ in bone marrow of CRPC patients | Estrogen receptors (ERα/ERβ); EZH2 | ↓ invasion and migration in vitro and vivo | [158–160] |
| Osteosarcoma and Ewing sarcoma | ↑ in serum correlating with worse overall survival; ↑ in tissues correlating with distant metastasis | E-cadherin, HMG1; SYK-target genes | ↓ cell proliferation and migration, cell cycle arrest, ↑ apoptosis, both in vitro and in vivo | [79] [165–168] |
| Bladder cancer | ↑ metastasis | EMT genes (E-cadherin, N-cadherin) | ↓ cell migration and metastasis | [85] [177–179] |
| Brain cancer | Positive association with III-IV WHO grades and tumor size; ↑ MALAT1 in temozolomide-resistant patients; ↓ overall survival | miR-155; FBXW7; ERK/MAPK pathway; MMP2; thymidylate synthase | ↓ tumor growth, migration and invasiveness in vitro; ↓ inhibition of tumor growth in vivo; restoration of temozolomide sensitivity; eradication of GBM stem cells | [180–186] |
| Endometroid endometrial carcinoma | Association with FIGO stages | PCDH10-Wnt/β-catenin; miR200c | ↓ cell proliferation, migration and invasion | [76, 140] |
| Gastric cancer | ↑ peritoneal metastasis; ↑ distant metastasis; ↓ overall survival of stage III and IV patients | miR-122/IGF-1R axis; PCDH10; miR-23b | ↓ cell proliferation, cell cycle progression, migration and invasion; ↑ apoptosis; abrogation of chemoresistance | [149–153] |
| Colorectal cancer | ↑ lymph-node metastases; ↓ overall survival | PRKA kinase anchor protein 9 (AKAP-9); CCL5; E-cadherin | Abrogation of EMT; reversion of oxaliplatin resistance | [173–176] |
| Tumor type          | Associated clinical features of high MALAT1 tumors                                                                                                                                                                                                 | MALAT1 molecular target(s)                      | Phenotypic effects induced by MALAT1 inhibition in preclinical models                                                                 | Reference(s) |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Pancreatic cancer   | ↑ overall survival; ↓ progression-free survival of patients undergoing gemcitabine-based chemotherapy as first-line treatment for locally advanced or advanced disease                                                                                           | Hippo-YAP1 pathway; P62, LAMP-2                  | ↓ cell proliferation and migration, ↑ of apoptosis, in vitro and in xenograft murine models in vivo                                                                                               | [154–157]    |
| Multiple myeloma    | ↑ MGUS, SMM, MM, and PCL; ↓ circulating MALAT1 in MM patients; ↑ MALAT1 in bone marrow mononuclear cells from MM patients                                                                                                                             | LTBP3; SP1; NRF1-NRF2/Keap1 pathway; proteasome-associated genes; miR-29b | ↓ of in vitro and in vivo tumor growth and induction of apoptosis; ↓ clonogenicity; ↑ sensitivity to bortezomib                                                                                   | [27, 81, 101, 190] |
| Mantle cell lymphoma| ↓ overall survival                                                                                                                                                                                                                                    | p21 and p27 cell cycle inhibitors              | ↓ of cell proliferation, ↑ sensitivity to apoptosis; cell cycle arrest at G1/S transition                                                                                                          | [192]        |
| T cell lymphoma     | ↓ overall survival                                                                                                                                                                                                                                     | PRC2 components                                | –                                                                                                                                                                                            | [193]        |
metastasis reduction; furthermore, MALAT1 loss decreased branching morphogenesis in MMTV-PyMT and Her2/neu-amplified tumor organoids, increased cell adhesion, and reduced migration. At the molecular level, MALAT1 knock-down halted the expression of splicing genes involved in differentiation and pro-tumorigenic pathways [131].

A potential role of MALAT1 in the breast stem cell compartment was proposed by Latorre et al., who demonstrated that MALAT1 regulated the stem cell marker CD133 via the interaction with the RNA-binding protein HuR (ELAVL1); HuR silencing in luminal non-metastatic breast cancer cells was sufficient to upregulate N-cadherin (CDH2) and CD133, thus leading to a mesenchymal-like and migratory phenotype. In the basal-like metastatic cell line MDA-MB231 and in primary TNBC cells, MALAT1-HuR repressor complex was absent from the CD133-regulatory region, and this was attributed to diminished expression of MALAT1, which, when overexpressed, decreased CD133 levels [132]. In BC cells, oncogenic splicing factor SRSF1 bridges MALAT1 to mutant p53 and ID4 proteins, favoring its chromatin association and thus inducing the expression of various VEGF-A isoforms, indicating a role of MALAT1 in the promotion of angiogenesis [133].

Interestingly, interrogation of dbEST database allowed the identification of an alternatively spliced MALAT1 transcript (Dsv-MALAT1) that was mainly underexpressed in breast tumor samples as compared to full length MALAT1, and which acted as an independent prognostic factor. Noteworthy, Dsv-MALAT1 expression associated with alterations of pre-mRNA alternative splicing machinery, and with the expression of the Drosophila DGCR8 complex required for miRNA biogenesis [129]. Surprisingly, recent work by Kwok et al. unveiled a tumor suppressive role of MALAT1 in BC and colorectal cancer, where MALAT1 was induced by the tumor suppressor PTEN and negatively affected the expression of genes implicated in migration and invasion, such as EpCAM and ITGB4 [134].

Cervical cancer
MALAT1 transcript was upregulated in cervical cancer (CC) as compared to normal cervix, and its expression correlated with worse overall survival in CC patients and associated with lymph-node metastasis [135]. Jiang and colleagues disclosed a direct correlation between MALAT1 and HPV in CC cell lines, suggesting that MALAT1 could be a potential biomarker for screening [136]. Loss of function studies by siRNAs demonstrated the tumor promoting role of MALAT1 in CC cell viability, proliferation, migration, and invasion both in vitro and in vivo [135, 137]. MALAT1 also regulated EMT in CC, as demonstrated by the decrease in EMT-related genes Vimentin and β-catenin, and the upregulation of E-cadherin gene upon MALAT1 silencing [138]. Furthermore, MALAT1 was linked with miR-375 in a feedback loop ultimately triggering EMT in CC cells. Indeed, the authors demonstrated that miR-375 targeted MALAT1, partly restored E-cadherin levels, and significantly reduced N-cadherin and the invasive capability of CC cells [139].

Endometroid endometrial carcinoma
Zhao et al. investigated the molecular mechanisms implicating MALAT1 in endometrial tumorigenesis and identified MALAT1 as a downstream target of the protocadherin10 (PCDH10) gene, a Wnt pathway negative regulatory element, shedding light on a novel targetable PCDH10-Wnt/β-catenin-MALAT1 axis [76]. In a recent study, MALAT1 was found targeted by miR-200c, which plays a negative role in tumor growth and EMT; accordingly, an inverse correlation between MALAT1 and miR-200c levels emerged in EEC tissues. Interestingly, authors found that strategies targeting the miR-200c/MALAT1 axis, mainly by miR-200 mimics or MALAT1 shRNAs, significantly impaired cell migration, invasion, and in vitro and in vivo EEC growth [140].

Hepatocellular carcinoma
MALAT1 is overexpressed in hepatocellular carcinoma (HCC) primary samples and cell lines [141], and its expression correlated with advanced tumor stages and reduced overall survival of HCC patients [78]; moreover, high MALAT1 levels correlated with major risk of HCC recurrence after liver transplantation [142]. Mutational signatures related to liver carcinogenesis, including MALAT1 and NEAT1 IncRNAs, were found in the Japanese population [143], although their clinical significance remains unexplored.

Interestingly, the carcinogen arsenite could transcriptionally induce MALAT1 via HIF2α, and MALAT1 was found upregulated in the sera of people exposed to arsenite as well as in HCC patients; in turn, MALAT1 was able to promote the disassociation of the von Hippel-Lindau (VHL) protein from HIF-2α, therefore alleviating VHL-mediated HIF-2α ubiquitination and degradation. Importantly, lentiviral shRNA targeting of MALAT1 reduced tumor growth in vivo in xenograft models of arsenite-transformed HCC cells, strengthening the role of MALAT1 in carcinogen-induced tumorigenesis [78].

Recently, Wang and colleagues [144] highlighted a novel mechanism by which MALAT1 is upregulated in HCC: indeed, they showed that the Yes-associated oncoprotein YAP1 increased MALAT1 at both transcriptional and post-transcriptional level, thus accelerating HCC proliferation. Moreover, Wu et al. highlighted a functional interaction between MALAT1 and the IncRNA
HULC-1, both overexpressed in HCC; such interaction was instrumental in promoting growth of liver cancer stem cells through induction of telomere repeat-binding factor 2 (TRF2) telomerase activity [145]. By elegant mechanistic studies performed in HepG2 cells, it was further shown that MALAT1 competed with Sirt1 deacetylase for the binding with DBC1 (depleted in breast cancer 1), thus releasing Sirt1 and enhancing its deacetylase activity. As a consequence, p53 was deacetylated and did not transactivate its pro-apoptotic target genes, leading to uncontrolled cell growth [146].

**Esophageal squamous cell carcinoma**

Different studies reported that MALAT1 is overexpressed in Esophageal squamous cell carcinoma (ESCC). Yao et al. first demonstrated that MALAT1 was highly increased in tumor lesions as compared to non-cancerous tissues, and correlated with shorter overall survival rate of ESCC patients. In vitro studies showed that siRNA-mediated depletion of MALAT1 decreased cell growth, the colony formation ability, as well as the migratory and invasive capabilities of ESCC cells, along with G2/M cell cycle arrest and apoptosis induction [147]. Additionally, MALAT1 could be considered a predictive marker of poor prognosis in patients undergoing radical resection of middle thoracic ESCC, since its expression positively correlated with pT stage, and patients with high MALAT1 levels had a higher T stage and a shorter disease-free and overall survivals [148].

Recently, Wang et al. confirmed MALAT1 overexpression in human ESCC as compared to matched adjacent non-cancerous tissues, with the highest expression in stages III-IV patients, as well as in lymph node metastasis.

In vitro studies revealed that knock-down of MALAT1 reduced cell proliferation, migration and number of tumor spheres representing putative stem cell-like cells, along with increasing cell apoptosis. Moreover, MALAT1 downregulation induced a decrease of β-catenin, Lin28, EZH2 and EMT stem genes as OCT4, while promoted E-cadherin expression. Of note, EZH2 overexpression completely reverted repression of β-catenin and Lin28 induced by MALAT1-targeting siRNAs, thus supporting EZH2-dependent activity of MALAT1 in ESCC.

In vivo studies showed that siRNA-mediated depletion of MALAT1 reduced tumor formation in mice and enhanced animal survival, supporting is potential as therapeutic target [102]. Interestingly, tumor suppressor miR-101 and miR-217 acted as post-transcriptional regulators of MALAT1, whose silencing induced cell cycle arrest by p21 and p27 upregulation, and b-MYB inhibition. miR-101 and miR-217 overexpression or MALAT1 knockdown via miRNA mimics and siRNAs respectively, inhibited migration and invasion capabilities of ESCC cells, and were accompanied by deregulation of MALAT1 downstream metastasis-associated genes MIA2, HNF4G, ROBO1, CCT4, and CTHRC1 [88].

**Gastric cancer**

There is a wealth of evidences about MALAT1 overexpression in gastric cancer (GC). Okugawa et al. reported that MALAT1 was significantly higher in GC tissues and cell lines respect to normal mucosa, and it significantly correlated with peritoneal metastasis in GC patients [149]. In addition, since tissue and plasma MALAT1 levels scored higher in GC patients with distant metastasis, MALAT1 could likely serve as a potential biomarker for GC metastases. Importantly, high plasma levels of MALAT1 independently correlated with poor prognosis of GC patients. In GC clinical specimens, MALAT1 expression was tightly associated with densities of endothelial vessels, and with vasculogenic mimicry [150]. Moreover, knock-down of MALAT1 in GC cells inhibited cell proliferation, cell cycle progression, migration and invasion, and promoted apoptosis. Mechanistically, miR-122-IGF-1R signaling was found involved in dysregulated MALAT1 expression. Indeed, enforced miR-122 expression inhibited, whereas miR-122 inhibitor increased MALAT1 in GC cell lines. miR-122-mediated regulation of MALAT1 involved IGF-1R, a target of miR-122, whose expression positively correlated with MALAT1 in GC cell lines [151]. Furthermore, Qi et al. confirmed MALAT1 overexpression in GC cell lines, where it promoted cellular migration and invasion by epigenetic effects involving EZH2 and suppression of the tumor suppressor protocadherin 10 (PCDH10). High expression of MALAT1 was associated with poorer overall survival of stage III and IV GC patients [152], thus underlining the prognostic power of MALAT1 in GC.

MALAT1 involvement in GC chemo-resistance was demonstrated by YiRen et al., who found high levels of MALAT1 in vincristine-resistant cells, where MALAT1 mechanistically promoted pro-survival autophagy. MALAT1 silencing by shRNAs sensitized GC cells to chemotherapeutics by upregulating miR-23b, a miRNA sponged by MALAT1, which suppressed chemo-induced autophagy and related chemoresistance [153].

**Pancreatic cancer**

By interrogating Gene Expression Omnibus, Oncomine, and The Cancer Genome Atlas databases, authors found MALAT1 significantly elevated in patients with pancreatic cancer, and ROC curves showed a moderate diagnostic power of MALAT1 expression. Interestingly, serum levels of MALAT1 and other two lncRNAs, PVT1, and HOTTIP, acted as biomarkers predicting efficacy of gemcitabine-based chemotherapy as first-line
treatment for locally advanced or advanced pancreatic cancer, with progression-free survival of patients with high and low MALAT1 expression levels being 3.0 and 3.7 months, respectively [154].

Several pathways, including mTOR and MAPK, were found to mediate MALAT1 oncogenic activity in PC, as predicted by in silico analyses [128, 155]. MALAT1 silencing by siRNAs antagonized tumor cell proliferation and migration, and triggered apoptosis, both in vitro and in xenograft murine models in vivo. At the molecular level, inhibitory effects on cell proliferation were also linked either to the blockade of the Hippo-YAP1 pathway, which is hyperactivated in multiple types of cancer [156], or to the suppression of cytoprotective autophagy [157].

**Prostate cancer**
MALAT1 was found overexpressed in prostate cancer (PCa), where it served as diagnostic urinary biomarker for predicting risk of PCa. MALAT1 score, defined as the ratio between MALAT1 and PSA mRNAs, was significantly higher in men with positive biopsy, and allowed to define a MALAT1-based model likely preventing 30.2–46.5% of unnecessary biopsies in PSA 4–10 ng/ml cohorts with a probability threshold of 25% [158]. In PCs cells and organotypic slice cultures of organ-confined prostate tumors, MALAT1 and the lncRNA HOTAIR were implicated in estrogen-mediated transcriptional regulation. Specifically, both MALAT1 and HOTAIR were regulated by estrogens, and controlled estrogen receptors’ function by interacting with ERα/ERβ; such interaction appeared necessary for a complete estrogen signaling both in vitro and in vivo. Upon treatment with 17β-estradiol, chromatin recruitment of HOTAIR increased, while that of MALAT1 decreased, indicating an opposite regulation and function for these two lncRNAs [159]. In addition, MALAT1 was highly expressed in bone marrow biopsy specimens of castration-resistant prostate cancer (CRPC) [160]. In line with an epigenetic role, Wang and colleagues identified MALAT1 as a regulator of EZH2 in CRPC cells, as MALAT1 interacted with and facilitated promoter occupancy and H3K27me3 activity of EZH2; furthermore, MALAT1 facilitated EZH2-mediated PCa cell invasion and migration and enhanced expression of EZH2 target genes [158].

**Ovarian cancer**
As shown by Zhou et al., MALAT1 is upregulated in ovarian cancer (OC) tissues, and its expression correlated with International Federation of Gynecology and Obstetrics (FIGO) stages. In vitro, MALAT1 overexpression prompted OC proliferation, migration and invasion, while its depletion led to the opposite effects, and also increased CDDP-sensitivity [161–163]. Interestingly, MALAT1 affected the expression of genes of the matrix metalloproteinase (MMP) family involved in extracellular matrix metabolism: specifically, MALAT1 knockdown caused upregulation of MMP13, and downregulation of MMP19 and metallopeptidase with thrombospondin type-1 motif (ADAMTS1) [161]. Furthermore, Lei et al. observed MALAT1 upregulation in OC cell lines and specimens, and identified a novel mechanism by which MALAT1 enhanced tumor cell growth by targeting miR-506 in the context of a negative feed-back loop.

Authors also disclosed a positive correlation between the expression of MALAT1 and iASPP, a member of the apoptosis-stimulating proteins of p53 (ASPP) family [164].

**Sarcoma**
MALAT1 is frequently upregulated in osteosarcoma (OS) primary tissues and cell lines, and the analysis of clinical samples demonstrated correlation of high serum levels of MALAT1 with reduced survival rate in OS patients [165]. MALAT1 was shown to promote OS cell growth and metastasis by different mechanisms. Huo et al. showed that MALAT1 transcription was activated by TGF-β; additionally, MALAT1 interaction with the PRC2 member EZH2 was capable to suppress E-cadherin expression, thus promoting OS metastasis [166]. Additionally, Liu et al. demonstrated that MALAT1 promoted OS cell growth by inducing HMGB1 activity through inhibition of its negative regulators miR-142-3p and miR-129-5p. Consistent with all these findings, siRNA-mediated knockdown of MALAT1 inhibited cell proliferation and migration, and induced cell cycle arrest and apoptosis in OS cells, both in vitro [167] and in vivo [168].

In Ewing sarcoma (EWS), a devastating soft tissue sarcoma affecting predominantly young individuals, MALAT1 was identified to be transcriptionally upregulated through a SYK/c-MYC axis, and to positively mediate SYK tyrosine kinase oncogenic activity [79].

**Renal cell carcinoma**
MALAT1 is frequently overexpressed in renal cell carcinoma (RCC) cell lines and primary tumor samples as compared to normal tissues; moreover, high MALAT1 expression associated with worse overall survival in RCC patients [169]. Intriguingly, fusion of the TFEB gene on chromosome 6p21.2 and MALAT1 gene on chromosome 11q13 was observed in RCC, and likely associated to favorable clinical prognosis [170].

In RCC cells, MALAT1 was positively regulated by VHL pathway through c-FOS transcription factor and promoted EMT features of tumor cells in a PRC2-dependent manner, since EZH2 depletion inhibited MALAT1-
dependent tumor-promoting activity [171]. Interestingly, MALAT1 positive effects on EMT were further ascribed to a ceRNA mechanism: through miR-200 sponging, MALAT1 upregulated zinc finger E-box-binding homeobox 2 (ZEB2), which in turn promoted proliferation and dissemination of RCC cells [172].

**Colorectal cancer**
MALAT1 was found upregulated in human primary colorectal cancer (CRC) tissues with lymph node metastasis. Clinically, high levels of MALAT1 and other IncRNAs, including AFAP1-AS1, BCA4R, H19, HOXA-AS2, and PVT1, were predictive of poor prognosis of CRC patients [173]. MALAT1 overexpression promoted CRC cell proliferation, invasion and migration in vitro, and stimulated tumor growth and metastasis in mice [174]. By genome-wide profiling, Yang et al. showed that among 243 genes regulated by MALAT1 in CRC cells, PRKA kinase anchor protein 9 (AKAP-9) was significantly upregulated at both mRNA and protein level. Of note, knockdown of AKAP-9 rescued MALAT1-induced CRC cell proliferation, migration and invasion. MALAT1 was also associated with colon cancer progression by stimulating tumor associated dendritic cells (TADC)-derived production of CCL5; consistently, MALAT1 blockade by siRNAs significantly dampened CCL5-induced migration and invasion of CRC cells [175].

Importantly, MALAT1 was shown to induce oxaliplatin-resistance partly through suppression of E-cadherin signaling and induction of EMT, acting in an EZH2-dependent manner; consistently, targeted inhibition of both MALAT1 and EZH2 via siRNAs reversed EMT features and restored oxaliplatin sensitivity [176].

**Bladder cancer**
Li et al. showed that high MALAT1 expression could serve as an independent prognostic factor for overall survival of patients with bladder cancer, and could be considered a potential therapeutic target [177]. Moreover, Ying and colleagues showed that MALAT1 promoted bladder cancer cell migration and metastasis by inducing EMT [178]. Mechanistically, MALAT1 association with PRC2-component Suz12 led to reduction of E-cadherin and induction of N-cadherin, triggering EMT in vitro and tumor growth and dissemination in vivo [85].

Serum MALAT1 was also found upregulated in bladder cancer patients compared to healthy individuals and could likely a represent a novel independent biomarker for the diagnosis or recurrence of this cancer [179].

**Brain cancer**
Ma et al. showed that MALAT1 is downregulated in glioma, where high expression correlated with improved survival in patients [180]. Interestingly, preliminary reports showed that MALAT1 acted as tumor-suppressor gene, thus suggesting that its restoration might be a novel therapeutic approach against glioma. In this light, Cao and colleagues demonstrated that MALAT1 inhibited cell viability by down-regulating miR-155 and promoting FBXW7 expression, a tumor suppressor promoting the degradation of substrates with oncogenic activity such as Cyclin E, c-Myc and AURKA [181]. Moreover, Han et al. revealed that upregulation of MALAT1 significantly reduced cell growth by inhibiting ERK/MAPK pathway and MMP2-mediated invasiveness both in vitro and in vivo [182]. Conversely, Vassallo et al. revealed that WNT inhibitory factor 1 WIF1 down-modulated MALAT1, whose expression in turn enhanced migration of tumor cells both in vitro and in vivo [183].

By deep sequencing analysis of temozolomide-sensitive and resistant patient glioma cells, MALAT1 was shown to discriminate responding from non-responding patients; moreover, MALAT1 was found to promote in vitro chemoresistance through miR-203 suppression, which is involved in cell proliferation pathway through thymidylate synthase targeting [184]. Additionally, by sponging miR-101, MALAT1 abolished miR-101-dependent negative regulation of the autophagic program in glioma cells, thus prompting cell proliferation [185].

Importantly, targeted nanocomplexes carrying MALAT1-targeting siRNAs were able to eradicate glioblastoma stem cells, leading to improved sensitivity of tumor cells to temozolomide in animal models of glioblastoma [186].

**Hematological malignancies**

**Multiple myeloma**
Cho et al. found MALAT1 overexpressed in bone marrow mononuclear cells from newly-diagnosed multiple myeloma (MM) patients as compared to treated patients or healthy individuals. Moreover, patients who experienced disease progression or relapse showed an increased expression of MALAT1; of note, MALAT1 expression in newly diagnosed patients did not correlate with the percentage of plasma cells in the bone marrow [187]. Our group and others recently confirmed progressive increase of MALAT1 levels from normal plasma cells to overt MM, and further increase in the extramedullary phases, in a large number of clinically-annotated patients [27] [188]. On the other hand, expression of circulating MALAT1 was significantly lower in MM patients [189].

Regarding MALAT1 mechanism of action, Ronchetti et al. showed that upregulation of MALAT1 in MM
associated with molecular pathways regulating cell cycle, p53-mediated DNA damage response, and mRNA maturation processes. Furthermore, Li et al. demonstrated that MALAT1 regulates the transcription of the neighboring antisense protein-coding gene LTBP3, a crucial regulator of bone formation, in mesenchymal stem cells from MM patients, with potential implications for MM-related bone disease. At the molecular level, investigators reported that the transcription factor SP1 is recruited by MALAT1 on the LTBP3 promoter, promoting an increase of LTBP3 expression [190]. Importantly, selective targeting of MALAT1 by LNA gapmeR ASOs triggered apoptosis in vitro and in vivo in a murine model of human MM and also overcame the protective bone marrow microenvironment, which is known to promote survival and drug resistance of MM cells. Intriguingly, MALAT1 ASO-knock-down inhibited all proteasome activities (trypsin-like, chymotrypsin-like, and caspase-like) by targeting the well-established positive regulators of proteasome gene expression NRF1 and NRF2, through EZH2-mediated regulation of the NRF1/2 negative regulator KEPAP1 [81].

Interaction between EZH2 and MALAT1 also impacted the miRNome, since inhibition of either MALAT1 or EZH2 via LNA gapmeR ASOs and small molecule EZH2 inhibitors respectively, reduced H3K27me3 repressive marks at miR-29a/b-1 promoter [101], with consequent upregulation of miR-29b, a relevant tumor suppressive miRNA in MM [30, 191].

**Lymphomas**

MALAT1 is abundantly expressed and associated with reduced overall survival of mantle cell lymphoma (MCL) patients. Of note, MALAT1 targeting by siRNAs blocked cell proliferation and increased apoptotic cell death. As seen in other neoplasias, Wang and colleagues also underscored an EZH2-mediated epigenetic activity of this lncRNA in MCL, since MALAT1 knock-down reduced EZH2 levels and decreased H3K27me3 at the promoter of the target genes p21WAF1 and p27KIP1, leading to cell cycle arrest at G1/S phase [192]. MALAT1 was also found to interact with, and to positively correlate with the expression of PRC2-components EZH2 and SUZ12, in NK and T cell lymphomas [193].

**Conclusions**

Multiple lines of evidence have reported aberrant expression and prognostic usefulness of tissue MALAT1 across several tumor types, along with diverse and context-dependent molecular mechanisms leading to the acquisition of the malignant phenotypes.

To date, the complex tridimensional structure of lncRNAs allowing interaction with many RNA and/or protein partners, along with the resultant pleiotropic mode of action, have slowed down acquisitions on lncRNA functions in normal and pathological contexts. In this regard, novel biochemical approaches to study lncRNAs are progressively emerging, and will likely disclose unknown functions of lncRNAs, including MALAT1, hopefully widening the spectrum of biological activities and the precise role in disease pathobiology.

Significant advances have been also achieved in developing therapeutic reagents for drugging oncogenic lncRNAs in tumor cells, and novel approaches are being addressed to design and develop small molecules targeting lncRNAs within their tridimensional conformations.

Overall, targeted genetic deletion of MALAT1 by zinc finger nucleases, as well MALAT1 therapeutic targeting by synthetic oligonucleotides, including siRNAs and the newly developed LNA gapmeR ASOs, have established the oncogenic role of this lncRNA and its druggability for therapeutic purposes.

Although additional studies with more sophisticated and physiologically relevant in vivo models recapitulating certain types of cancers are undoubtedly required, available findings indeed point to MALAT1 as lead candidate for novel clinically translatable lncRNA-based therapeutic strategies against cancer.

**Abbreviations**

AFAP1-AS1: AFAP1-antisense RNA; AIM1: Absent in melanoma 1; AKAP-9: A-Kinase anchoring protein 9; AMACAR: Alpha-methylacyl-CoA racemase; BCAR4: Breast cancer anti-estrogen resistance 4; BCL2: B cell lymphoma 2; BDNF-AS1: Brain-derived neurotrophic factor antisense 1; CC: Cervical cancer; CCAT1: Colon cancer-associated transcript 1; CCL5: Chemokine C-C motif ligand 5; CCT4: Chaperonin Containing TCP1 subunit 4; CD133: Cluster of differentiation 133; CDKN1A: Cyclin-dependent kinase inhibitor 1A; CDKN2B: Cyclin-dependent kinase inhibitor 2B; ceRNA: Competing endogenous RNA; c-FOS: FBJ osteosarcoma oncogene; CRC: Colorectal cancer; CRPC: Castration-resistant prostate cancer; CTHRC1: Collagen triple helix repeat containing 1; CXCL5: C-X-C motif chemokine ligand 5; DLEU1: Deleted in leukaemia; DSCAM-AS1: Down syndrome core cell adhesion molecule antisense RNA 1; EEC: Endometroid endometrial carcinoma; EMT: Epithelial-to-mesenchymal transition; ER: Estrogen receptor; ERK: Extracellular signal-regulated kinase/mitogen-activated protein kinase; ESCC: Esophageal squamous cell carcinoma; EZH2: Enhancer of zeste homolog 2; FBXW7: F-Box and WD repeat domain containing 7; FHL1: Four and a half LIM domains 1; GC: Gastric Cancer; H3K27me3: Histone H3 lysine 27 trimethylated; H3K6me2: Histone H3 lysine 36 dimethylated; HCC: Hepatocellular carcinoma; HMVR: Hyaluronan-mediated motility receptor; hnrRNA: Heterogeneous nuclear ribonucleoprotein k; HOTAIR: HOX transcript antisense RNA; HOXA-AS2: HOXA cluster antisense RNA 2; HOXB13: Homeobox B13; HULC-1: Hepatocellular carcinoma upregulated long non-coding RNA; HuR: Hu antigen R; iASPP: Inhibitor of apoptosis-stimulating protein of p53; IGF-1R: Type I insulin-like growth factor receptor; JMJD1A: Jumonji C-domain-containing protein 1A; LAYN: Layilin; LncRNA: Long non-coding RNA; LTRBP3: Latent transforming growth factor beta-binding protein 3; MALAT1: Metastasis associated lung adenocarcinoma transcript 1; miRNA: MicroRNA; MMP: Matrix metalloproteinase; MMTV: Mouse mammary tumor virus-PyMT; MREs: miRNA response elements; NALT: Notch1 associated lncRNA in T-ALL; nRNA: Non-coding RNA; NEAT1: Nuclear-enriched abundant transcript 1; NF-YA: Nuclear transcription factor Y subunit alpha; NK: Natural killer; NSCLC: Non-small cell lung cancer; OCT4: Octamer-binding transcription factor 4; OS: Osteosarcoma; PCa: Prostate cancer; PCAT-1: Prostate cancer-associated transcript 1; PCDH10: Protocadherin10 gene; pRNA: Piwi-interacting RNA; PRC2: Polycomb repressive complex 2; PSA: Prostate specific antigen; PSMA: Prostate-specific membrane antigen; PVT1: Plasmacytoma variant...
translocation gene 1; RCC: Renal cell carcinoma; ROD1: Regulator of differentiation 1; SET: SET nuclear proto-oncogene; siRNA: Small interfering RNA or short interfering RNA or silencing RNA; SIRT1: Sirtuin-1; SLC26A2: Solute carrier family 26 member a2; snRNA: Small nuclear RNA; SPRY4: Sprouty RTK signaling antagonist 4; SR: Serine- and arginine-rich; SUZ12: Suppressor of zeste 12 protein homolog; TADG: Tumor-associated dendritic cells; T-A LL: T-acute lymphoblastic leukaemias; TDP43: TAR DNA-binding protein 43; TNBC: Triple-negative breast cancer; TRF2: Telomere repeat-binding factor 2; VHL: Von Hippel-Lindau; WHO: World Health Organization; WFI1: Wnt inhibitory factor 1; YAP: Yes-associated protein; ZEB2: Zing finger E-box-binding homeobox 2

Acknowledgements
We thank Dr. Ivana Cirititi and Dr. Alessandra Crescini for precious editorial and laboratory assistance.

Funding
This study was funded by Italian Association for Cancer Research (AIRC) with “Special Program for Molecular Clinical Oncology-5 per mille”, 2010/15 and its “Extension Program” No. 9980, 2016/18 (PI: PT); and also by “Innovative Immunotherapeutic Treatments of Human Cancer” Multi Unit Regional No. 16695 (cofinanced by AIRC and the CARICAL foundation).

Availability of data and materials
The data supporting the conclusion of this review have been included within the article.

Authors’ contributions
NA conceived the review. MAS, GJ, DC, and LR collected the references and participated in the discussion. NA drafted the manuscript. PT and PT provided critical evaluation of and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This is not applicable for this review.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Experimental and Clinical Medicine, Magna Graecia University, Viale Europa, 88100 Catanzaro, Italy. 2IRC5 Rizzoli Orthopedic Institute, Bologna, Italy. 3Innovative Technology Platforms for Tissue Engineering, Theranostics and Oncology, Rizzoli Orthopedic Institute, Palermo, Italy.

Received: 21 February 2018 Accepted: 26 April 2018
Published online: 08 May 2018

References
1. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Karlsson B, et al. Landscape of transcription in human cells. Nature. 2012;489(7414):101–8.
2. Martinov I, Ramadass A, Serra Barros A, Chow N, Akoulitchev A. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. Nature. 2007;445(7128):666–70.
3. Tian D, Sun S, Lee JT. The long noncoding RNA, jpx, is a molecular switch for X chromosome inactivation. Cell. 2010;143(3):390–403.
4. Lee JT, Bartolomei MS. X-inactivation, imprinting, and long noncoding RNAs in health and disease. Cell. 2013;152(6):1308–23.
5. Bartolomei MS, Zemel S, Tilghman SM. Parental imprinting of the mouse H19 gene. Nature. 1991;351(6322):153–5.
6. Sleutels F, Zwart R, Barlow DP. The non-coding air RNA is required for silencing autosomal imprinted genes. Nature. 2002;415(6873):810–3.
7. Fatica A, Bozzori I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21.
8. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298–307.
9. Gabili MN, Trapnell C, Goff L, Kozoll M, Tiazon-Vega B, Riegev A, Rinn JL. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2012;25(18):1915–27.
10. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904–14.
11. Lee JT. Epigenetic regulation by long noncoding RNAs. Science. 2012;338(6133):1435–9.
12. Gong C. Maquat LE. IncRNAs transactivate STA U1-mediated mRNA decay by duplexing with 3’ UTRs via Alu elements. Nature. 2011;470(7333):284–8.
13. Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA. 2010;16(11):2043–50.
14. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A cell RNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353–5.
15. Hrdlickova B, de Almeida RC, Borek Z, Wothoff S. Genetic variation in the non-coding genome: involvement of micro-RNAs and long non-coding RNAs in disease. Biochim Biophys Acta. 2014;1842(10):1910–22.
16. Spizzo R, Almeida Mi, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31(43):5428–39.
17. Volders PJ, Verhegggen K, Menschaert G, Vandepoele K, Martens L, Vandesompele J, Mentagh P. An update on LNCipedia a database for annotated human IncRNA sequences. Nucleic Acids Res. 2015;43(Database issue):D174–80.
18. Amaral PP, Clark MB, Gascoigne DK, Dinger ME. Mattick JS: lncRNAdb: a reference database for long non-coding RNAs. Nucleic Acids Res. 2011;39(Database issue):D146–51.
19. Harrow J, Frankish A, Gonzalez JM, Tapasani M, Diekhans M, Kokocinski F, Aken B, Barrell D, Zadisa A, Searle S, et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012;22(9):1976–70.
20. Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int. 2013;2013:136316.
21. Bu D, Yu K, Sun S, Xie C, Skogermo G, Miao R, Xiao H, Liao Q, Luo H, Zhao G, et al. NONCODE v3.0: integrative annotation of long noncoding RNAs. Nucleic Acids Res. 2012;40(Database issue):D210–5.
22. Zheng Y, Liu L, Shukla GC. A comprehensive review of web-based non-coding RNA resources for cancer research. Cancer Lett. 2017;407:1–8.
23. Dohner H, Stilgenbauer S, Benner A, Leupold E, Khor B, Mullinger L, Dohner K, Benzt M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2003;348(28):1910–6.
24. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102(39):13944–9.
25. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Imp佐 M, Califano A, Migliazza A, Bhagat G, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17(1):28–40.
26. Neboli L, Lionetti M, Neri A. Long non-coding RNAs in normal and malignant hematopoiesis. Oncotarget. 2016;7(13):20666–81.
27. Ronchetti D, Agnelli L, Taiana E, Galletti S, Manzoni M, Todero M, Musto P, Strozzi F, Neri A. Distinct IncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma. Oncotarget. 2016;7(12):14814–30.
28. Guan Y, Ku W, Stilwell JI, Takano H, Lakup AV, Fliyand J, Mao JH, Yu M, Miller MA, Santos JL, et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res. 2007;13(19):5745–58.
29. Loewen G, Jayavickramarajah J, Zhuo Y, Shan B. Functions of IncRNA NOTCH1 in lung cancer. J Hematol Oncol. 2014;7:90.
30. Amadio N, D’Aquila P, Passarino G, Tassone P, Bellizzi D. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation. Expert Opin Ther Targets. 2012;16(11):91–101.
31. Zhang C, Wang X, Li X, Zhao N, Wang Y, Han J, Luo H, Zhao G, et al. HOTAIR in lung cancer. J Hematol Oncol. 2014;7:90.
32. Wang KC, Li KK, Lau KM, Ng YL, Wong J, Chung NY, Li HW, Chui YL, Liu WW, Chen ZP, et al. KIAA0495/PDAM is frequently downregulated in oligodendrogliomas and its knockdown by siRNA induces cisplatin resistance in glioma cells. Brain Pathol. 2010;20(6):1021–32.
33. Benetatos L, Hatzipimichi E, Dasoula A, Dranitsaris G, Tsara S, Syrrou M, Georgiou I, Bourantas KL. CpG methylation analysis of the MEG3 and...
SNRNPs imprint genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2010;34(2):148–53.

35. Benetatos L, Dasoula A, Hatzimichael E, Georgiou J, Syrrou M, Bourantas KL. Promoter hypermethylated of the MEIS1 (DLK1/MEG3) imprinted gene in multiple myeloma. Clin Lymphoma Myeloma. 2008;8(3):171–5.

36. Dong Z, Zhang A, Liu S, Lu F, Guo Y, Zhang G, Xu F, Shi Y, Shen S, Liang J, et al. Ablentor methylated-mediated silencing of IncRNA MEG3 functions as a ceRNA in esophageal cancer. Mol Cancer Res. 2017;15(7):800–10.

37. Abdil J, Rastgoo N, Li L, Chen W, Chang H. Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis. J Hematol Oncol. 2017;10(1):139.

38. Halaby MJ, Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J, Fang G. Up-regulated long non-coding RNA H19 indicates a poor prognosis and affects cell proliferation in non-small-cell lung cancer. Tumour Biol. 2016;37(3):4007–15.

39. Caramusso L, Contino F, Ferro A, Minnafri A, Peronti G, Gaillongo A, Feo S. The PVT1 oncogene is a Myc protein target that is overexpressed in transformed cells. J Cell Physiol. 2007;213(1):511–8.

40. Timarchi T, Bilal E, Ntzitzichristos P, Fabbri G, Dalla-Favera R, Tsirigos A, Atlantis I. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell. 2014;158(3):593–606.

41. Wang Y, Wu P, Lin R, Lue L, Xue Y, Fang Y. LncRNA NALT interaction with NOTCH1 promoted cell proliferation in pediatric T cell acute lymphoblastic leukemia. Sci Rep. 2015;5:17394.

42. Sun M, Gadad SS, Kim DS, Kraus WL. Discovery, annotation, and functional analysis of long noncoding RNAs controlling cell cycle gene expression and proliferation in breast cancer cells. Mol Cell. 2015;59(4):698–711.

43. Danko CG, Hah N, Luo X, Martins AL, Core L, Lis JT, Siepel A, Kraus WL. Signaling pathways differentially affect RNA polymerase II initiation, pausing, and elongation rate in cells. Mol Cell. 2013;50(2):1212–22.

44. Hahn WH, Germani S, Nabi AG, Danko CG, Kraus WL. Enhancer transcripts mark active estrogen receptor binding sites. Genome Res. 2013;23(8):1210–23.

45. Miano V, Ferrero G, Reineri S, Caizzi L, Annaratone L, Ricci I, Cuprui S, Castellano I, Cordero F, De Bertoli M. Luminal long non-coding RNAs regulated by estrogen receptor alpha in a ligand-independent manner show functional roles in breast cancer. Oncotarget. 2016;7(13):13201–16.

46. Chakravarty D, Stover A, Nair SS, Giannopoulos E, Li R, Henning S, Mosquera JM, Pauwells J, Park K, Kossai M, et al. The oestrogen receptor alpha-regulated IncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun. 2014;5:3838.

47. P J, Pudererich S, Wang W, Boings S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, bulk E, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):5031–41.

48. Eismann M, Gruenberger H, Hammermeier M, Gunther S, Caudron-Herger M, Gross M, Schirnhacher P, Rippe K, Braun T, Zornig M, et al. Loss of the PVT1 oncogene is a Myc protein target that is overexpressed in transformed cells. J Cell Physiol. 2007;213(1):511–8.

49. Hsiao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B. Tumour-suppressor DNA hypermethylated of the MEIS1 (DLK1/MEG3) imprinted gene in multiple myeloma. Clin Lymphoma Myeloma. 2008;8(3):171–5.

50. Dong Z, Zhang A, Liu S, Lu F, Guo Y, Zhang G, Xu F, Shi Y, Shen S, Liang J, et al. Ablentor methylated-mediated silencing of IncRNA MEG3 functions as a ceRNA in esophageal cancer. Mol Cancer Res. 2017;15(7):800–10.
98. Zhang B, Arun G, Mao YS, Lazar Z, Jiang W, Zhang J, Dhiggi KA, Grinstein JD, Dorrestein PC. Rosfiedel Mt. mG-ncRNA and Pbx2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell. 2011;147(7):733–78.

99. Engreitz JM, Strookman K, McDonell P, Shishkin AA, Surka C, Russell P, Grossman SR, Chow ATY, Guitman M, Lander ES. RNA-RNA interactions enable specific targeting of noncoding RNAs to nascent pre-mRNAs and chromatin sites. Cell. 2014;159(1):188–99.

100. Stamato MA, Juli G, Romeo D, Ronchetti D, Arbitrio M, Caracciolo D, Neri A, Tagliarferri P, Tassone P, Amadini N. Inhibition of EZH2 triggers the tumor suppressor miR-29b network in multiple myeloma. Oncotarget. 2017;8(63):106527–37.

101. Wang Z, Zhu Y, Li S, Chen X, Jiang G, Shen Z, Qiao Y, Wang L, Zheng P, Zhang Y. Long non-coding RNA MALAT1 promotes malignant development of esophageal squamous cell carcinoma by targeting beta-catenin via EZH2. Oncotarget. 2016;7(18):25688–92.

102. Chang SM, Hu WW. Long non-coding RNA MALAT1 promotes oral squamous cell carcinoma development via microRNA-125b-STAT3 axis. J Cell Physiol. 2017;232(4):1638–48.

103. Luan W, Li L, Shi Y, Bu X, Xia Y, Wang J, Djangmah HS, Liu X, You Y, Xu B. Long non-coding RNA MALAT1 as a competing endogenous RNA to promote malignant melanoma growth and metastasis by sponging miR-22. Oncotarget. 2016;7(39):63901–12.

104. Shi XS, Li J, Yang RH, Zhao GR, Zhou HP, Zeng WX, Zhou M. Correlation of increased MALAT1 expression with pathological features and prognosis in cancer patients: a meta-analysis. Genet Mol Res. 2015;14(4):18888–19.

105. Wang J, Xu AM, Zhang YJ, He WM, Pan YS, Cheng G, Qin C, Hua LX, Wang ZJ. Prognostic significance of low non-coding RNA MALAT1 in various human carcinomas: a meta-analysis. Genet Mol Res. 2016, 15(1).

106. Nobilega OA, Occhavenko I, Afsal V, Rubin EM. Scanning human genome deserts for long-range enhancers. Science. 2003;302(5644):413.

107. Cheng J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc. 2014;7(3):35–50.

108. Geary RS, Nordi D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;78:476–51.

109. Shin X, Corey DR. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 2017;

110. Lundin KE, Hojland T, Hansen BR, Persson R, Bramsen JB, Kjems J, Koch T, Wengel J, Smith CI. Biological activity and biotechnological aspects of locked nucleic acids. Adv. Ther. 2013;82:427–107.

111. Amadini N, Di Martino MT, Neri A, Tagliarferri P, Tassone P. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther. 2013;13(Suppl 1):S125–37.

112. Genot M, Servicic M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9(10):775–89.

113. Amadini N, Rossi M, Raimondi L, Pitati MR, Botta C, Tagliarferri P, Tassone P. miR-29a: a family of ep-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget. 2016;7(44):6927–61.

114. Gulla A, Di Martino MT, Gallo Cantofo ME, Morelli E, Amadini N, Botta C, Pitati MR, Lio SG, Brittii D, Stamato MA, et al. A 13 mer LNA-miR-221 inhibitor restores drug sensitivity in melphalan-resistant multiple myeloma cells. Clin Cancer Res. 2016;22(5):1222–33.

115. Calura E, Bisognin A, Marzoni M, Toddei K, Taiana E, Sales G, Morgan JG, Tonon G, Amadini N, Tassone P, et al. Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. Oncotarget. 2016;7(13):12367–78.

116. Raimondi L, De Luca A, Morelli E, Giavaresi G, Tagliarferri P, Tassone P, Amadini N. MicroRNAs: novel crossroads between myeloma cells and the bone marrow microenvironment. Biomed Res Int. 2016;2016:504939.

117. Gallo Cantofo ME, Nielsen BS, Wignogna C, Arbitrio M, Botta C, Frandsen NM, Rolfo C, Tagliarferri P, Tassone P, Di Martino MT. Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates. Mol Ther Nucleic Acids. 2016;5(6).

118. Di Martino MT, Gulla A, Gallo Cantofo ME, Attomare E, Amadini N, Leone E, Morelli E, Lio SG, Caracciolo D, Rossi M, et al. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cell lines. PLoS One. 2014;9(4):e89059.

119. Di Martino MT, Rossi M, Caracciolo D, Gulla A, Tagliarferri P, Tassone P, Mir-221/222 are promising targets for innovative anticancer therapy. Expert Opin Ther Targets. 2016;20(9):1099–108.

120. Fulciniti M, Amadini N, Bandi RL, Cagnetta A, Samur MK, Achaya C, Prabhala R, D’Aquilla P, Bellizzi D, Passarino G, et al: miR-23b/SF1/c-myc forms a
metastatic castration-resistant prostate cancer. Mol Cancer Res. 2015;13(1):98–106.

165. Zhou Y, Xu X, Lu H, Wen Q, Li J, Tan L, Li J, Sheng X. The long non-coding RNA MALAT-1 is highly expressed in ovarian cancer and induces cell growth and migration. Placenta. 2016;11(3):e1552-250.

166. Wu L, Wang X, Guo Y. Long non-coding RNA MALAT1 is upregulated and involved in cell proliferation, migration and apoptosis in ovarian cancer. Exp Ther Med. 2017;13(6):3055–60.

167. Bai L, Wang A, Zhang Y, Xu X, Zhang X. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway. Exp Cell Res. 2018;366(2):161–71.

168. Lei R, Xue M, Zhang L, Lin Z. Long noncoding RNA MALAT1-regulated microRNA S06 modulates ovarian cancer growth by targeting JASPR. Oncotarget. 2017;10:3355–46.

169. Fellenberg J, Bernd L, Deling G, Wette D, Zahn-Hentingarane A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol. 2007;20(10):1085–94.

170. Hsio Y, Li Q, Wang X, Xiao X, Zheng J, Li Z, Pan X. MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2. Oncotarget. 2017;8(24):46993–7006.

171. Liu K, Huang J, Ni J, Song D, Ding M, Wang J, Huang X, Li W. MALAT1 promotes osteosarcoma development by regulation of HKG1 via miR-142-3p and miR-129-5p. Cell Cycle. 2017;16(8):578–87.

172. Cai X, Liu Y, Yang W, Xia Y, Yang C, Yang S, Liu X. Long noncoding RNA MALAT1 as a potential therapeutic target in osteosarcoma. J Orthop Res. 2016;34(6):932–41.

173. Zhang HM, Yang FQ, Chen SJ, Che J, Zheng JH. Upregulation of long noncoding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma. Tumour Biol. 2015;36(4):2947–55.

174. Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, Srinivasan R, Linehan WM. Molecular genetics and cellular features of TFE3 in clear cell renal cell carcinoma. Tumour Biol. 2015;36(4):2947–55.

175. Kan JY, Wu DC, Yu FJ, Wu CY, Ho YW, Chiu YJ, Jian SF, Hung JY, Wang JY, et al. Differentially expressed long non-coding RNAs in bladder cancer contribute to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol BioSyst. 2012;8(9):2289–94.

176. Duan W, Du L, Jiang X, Wang R, Yan S, Xie Y, Yan K, Wang Q, Wang L, Zhang X, et al. Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer. Oncotarget. 2016;7(48):78850–8.

177. Ma KX, Wang HJ, Li XR, Li T, Su G, Yang P, Wu JW. Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma. Tumour Biol. 2015;36(6):3355–9.

178. Cao S, Wang Y, Li J, Lv M, Niu H, Tian Y. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBW7 function. Am J Cancer Res. 2016;6(1):2561–74.

179. Han Y, Wu Z, Liu T, Huang Y, Cheng Z, Li X, Sun T, Xie X, Zhou Y, Du Z. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis. 2016;7:e2123.

180. Vasallo I, Zinn P, Lai M, Rajanekar P, Harcou MF, Hegi ME. WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the IncRNA MALAT1. Oncogene. 2016;35(12):21–32.

181. Chen W, Xu XK, Li JL, Kong KK, Li H, Chen C, He J, Wang F, Li P, Ge XS, et al. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget. 2017;8(14):22783–99.

182. Fu Z, Luo W, Jiang P, Peng T, Sun G, Shi J, Li Z, Zhang B. MALAT1 activates autophagy and promotes cell proliferation by sponging miR-101 and upregulating STIMATE, RAB5A and ATGAD expression in glioma. Biochem Biophys Res Commun. 2017;492(3):480–6.

183. Kim SS, Harford JB, Moghe M, Aitt A, Pirollo KF, Chang EH. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res. 2017.

184. Cho SF, Chang YC, Chang CS, Lin SF, Liu YC, Hsiao HH, Chang JG, Liu TC. MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. BMC Cancer. 2014;14:809.

185. Haneda H, Kuroda Y, Kimura K, Masuda Y, Hattori A, Alkessi L, Matsumoto M, Kasamatsu T, Kobayashi N, Tahara KI, et al. Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma. Br J Haematol. 2017.

186. Isin M, Ozgur E, Cetin G, Erten N, Aytan M, Gezer U, Dalay N. Investigation of circulating IncRNAs in B-cell neoplasms. Clin Chim Acta. 2014;431:255–9.

187. Li B, Chen P, Qu J, Shi L, Zhan W, Fu J, Li J, Zhang X, Sun Y, Zhaung W. Activation of TBPF3 gene by a long non-coding RNA (IncRNA) MALAT1 transcript in mesenchymal stem cells from multiple myeloma. J Biol Chem. 2014;289(42):29365–75.

188. Amodio N, Stamatou MA, Gulla AM, Morell E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, et al. Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016;15(6):1364–75.

189. Wang X, Sehgal L, Jain N, Khabab T, Mathur R, Sananiando F. LncRNA MALAT1 promotes development of mante cell lymphoma by associating with EZH2. J Transl Med. 2016;14(1):346.

190. Kim SH, Kim SH, Yang WI, Kim SJ, Yoon SO. Association of the long non-coding RNA MALAT1 with the polycomb repressive complex pathway in T and NK cell lymphoma. Oncotarget. 2017;8(19):31505–17.

191. Huang NS, Chi YY, Xue JY, Liu MY, Huang S, Mo M, Zhou SL, Wu J. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer. Oncotarget. 2016;7(25):37957–65.

192. Chen Q, Su Y, He X, Zhao W, Wu C, Zhang W, S X, Dong B, Zhao L, Gao Y, et al. Pleural long non-coding RNA MALAT1 is associated with distant metastasis in patients with epithelial ovarian cancer. Oncol Lett. 2016;12(2):1361–6.

193. Yang K, Hou Y, Li A, Li Z, Wang W, Xie H, Rong Z, Liu Q, Li K. Identification of a six-lncRNA signature associated with recurrence of ovarian cancer. Sci Rep. 2017;7(1):752.